NDAORALTABLET, EXTENDED RELEASE
Approved
Oct 2017
Lifecycle
LOE Approaching
Competitive Pressure
25/100
Clinical Trials
20
Data completeness
6/8 — Strong
LYRICA CR (pregabalin) by Viatris (2) is 2 ‑delta site (an auxiliary subunit of voltage‑gated calcium channels) in central nervous system tissues. First approved in 2017.
Drug data last refreshed 7h ago · AI intelligence enriched 12h ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LYRICA CR is an extended-release oral formulation of pregabalin, a small-molecule CNS agent that binds to the alpha-2-delta subunit of voltage-gated calcium channels to reduce pro-nociceptive neurotransmitter release in the spinal cord. It is indicated for neuropathic pain conditions and works through modulation of descending noradrenergic and serotonergic pain pathways, distinct from GABA, opioid, or monoamine reuptake mechanisms. The CR formulation provides sustained dosing to improve patient compliance and tolerability.
$0.4MPart D
LOE ApproachingDeclining
9mo to LOELYRICA CR faces imminent loss of exclusivity with minimal Part D penetration, signaling a transition from growth to legacy management and likely team contraction.
Mechanism of Action
2 ‑delta site (an auxiliary subunit of voltage‑gated calcium channels) in central nervous system tissues. Although the mechanism of action of pregabalin has not been fully elucidated, results with genetically modified mice and with compounds structurally related to pregabalin (such as gabapentin)…
Indications
Worked on LYRICA CR at Viatris (2)? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.